Synthesis of poly[APMA]-DOTA-64Cu conjugates for interventional radionuclide therapy of prostate cancer: Assessment of intratumoral retention by micro-positron emission tomography

Molecular Imaging

Volumn 6, Issue 1, 2007, Pages 10-17

  Yuan, Jianchao ^a   You, Yezi ^a   Lu, Xin ^a   Muzik, Otto ^a   Oupicky, David ^a   Peng, Fangyu ^a,b  

^a WAYNE STATE UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERVENTIONAL RADIONUCLIDE THERAPY; PROSTATE CANCER; RADIOPHARMACEUTICALS;

DYNAMIC LIGHT SCATTERING; FREE RADICAL POLYMERIZATION; INITIATORS (CHEMICAL); ONCOLOGY; POSITRON EMISSION TOMOGRAPHY; PRECIPITATION (CHEMICAL); SIZE EXCLUSION CHROMATOGRAPHY; SYNTHESIS (CHEMICAL);

CONJUGATED POLYMERS;

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ACRYLIC ACID RESIN; AZOBIS(ISOBUTYRONITRILE); NITRILE; ORGANOMETALLIC COMPOUND; POLY(N (3 AMINOPROPYL)METHACRYLAMIDE) DOTA 64CU CONJUGATE; POLY(N-(3-AMINOPROPYL)METHACRYLAMIDE)-DOTA-64CU CONJUGATE; RADIOPHARMACEUTICAL AGENT; SINGLE HETEROCYCLIC RINGS; UNCLASSIFIED DRUG;

ANIMAL; ARTICLE; CHEMISTRY; DRUG SCREENING; HUMAN; LIGHT; MALE; METABOLISM; MOUSE; MOUSE STRAIN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PROSTATE TUMOR; RADIATION SCATTERING; SYNTHESIS;

ACRYLIC RESINS; ANIMALS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; LIGHT; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MICE; MICE, INBRED STRAINS; NITRILES; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; SCATTERING, RADIATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34247381707     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2006.00030     Document Type: Article

References (24)

1. Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64.
2. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2002;52:23-47.
3. Bagshaw MA, Ray GR, Pistenma DA, et al. External beam radiation therapy of primary carcinoma of the prostate. Cancer 1975;36:723-8.
4. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res 2002;62:4968-76.
5. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled 1591 monoclonal antibodies: effect of multiple treatments on myelotoxidty. Clin Cancer Res 2005;11:7195-200.
6. Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases. Cancer 1999;85:980-7.
7. Schumacher T, Hofer S, Eichhorn K, et al. Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study. Eur J Nucl Med 2002;29:486-93.
8. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637-44.
9. 188Re labeled cationic polyethylenimine conjugates: a preliminary report. I Korean Med Sci 2004;19:647-51.
10. Kwak C, Hong SK, Seong SK, et al. Effective local control of prostate cancer by intratumoral injection of (166)Ho-chitosan complex (DW-166HC) in rats. Eur J Nucl Med Mol Imaging 2005;32:1400-5.
11. Mitra A, Nana A, Papadimitriouc JC, et al. Polymer-peptide conjugates for angiogenesis targeted tumor radiotherapy. Nucl Med Biol 2006;33:43-52.
12. Anderson CI, Lewis JS. Radiopharmaceuticals for targeted radiotherapy of cancer. Expert Opin Ther Pat 2000;10:1057-69.
13. Apelgot S, Coppey J, Gaudemer A, et al. Similar lethal effect in mammalian cells for two radioisotopes of copper with different decay schemes, 64Cu and 67Cu. Int J Radiat Biol 1989;55:365-84.
14. Connett IM, Anderson CJ, Guo LW, et al. Radioimmunotherapy with a 64Cu-labeled monoclonal antibody: a comparison with 67Cu. Proc Natl Acad Sd U S A 1996;93:6814-8.
15. Moi MK, Meares CF, McCall MJ, et al. Copper chelates as probes of biological systems: stable copper complexes with a macrocydic bifunctional chelating agent. Anal Biochem 1985;148:249-53.
16. Boswell AC, Sun X, Niu W, et al. Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocydic complexes. I Med Chem 2004;47:1465-74.
17. Grabarek Z, Gergely J. Zero-length crosslinking procedure with the use of active esters. Anal Biochem 1990;185:131-5.
18. Peng F, Liu J, Wu J, et al. Mouse extra-hepatic hepatoma detected on microPET using copper (II)-64 chloride uptake mediated by endogenous mouse copper transporter 1. Mol Imaging Biol 2005;7:325-9.
19. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994;13:601-9.
20. Rihova B, Bilej M, Vetvicka V, et al. Biocompatibility of N-(2-hydroxypropyl) methacrylamide copolymers containing Adriamycin. Biomaterials 1989;10:335-42.
21. Seymour LW, Miyamoto Y, Maeda H, et al. Influence of molecular weight on passive tumor accumulation of a soluble macromolecular drug carrier. Eur J Cancer 1995;31:766-70.
22. Nishikawa M, Hashida M. Pharmacokinetics of anticancer drugs, plasmid DNA, and their delivery systems in tissue-isolated perfused tumors. Adv Drug Deliv Rev 1999;40:19-37.
23. Mitra A, Mulholland J, Nan A, et al. Targeting tumor angiogenic vasculature using polymer-RGD conjugates. J Control Release 2005;102:191-201.
24. Line BR, Mitra A, Nan A, Ghandehari H. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates. J Nucl Med 2005;46:1552-60.